Osteoporosis

Osteoporosis is a systematic skeletal disease characterized by low bone mass, increase of bone fragility and susceptibility to fracture.


Types of Osteoporosis and its causes

- 1. Primary osteoporosis(Type I (postmenopausal) or Type II (senile)):
 - 1. Type I (postmenopausal): Generally develops in women after menopause when the amount of estrogen in the body greatly decreases. This process leads to an increase in the resorption of bone (the bones loses substance).
 - *Type II (senile):* This involves a thinning of both the trabecular bone (the spong bone inside of the hard cortical bone) and the hard cortical bone. This process often leads to hip and vertebral body (in the spine) fractures. 2.
- 2. Secondary osteoporosis: Secondary osteoporosis has the same symptoms as primary osteoporosis. However, it occurs as a result of having certain medical conditions, such as hyperthyroidism or leukemia. It may also occur as a result of taking medications known to cause bone breakdown, such as oral or high-dose inhaled corticosteroids (if used for more than 6 months), too high a dose of thyroid replacement, or aromatase inhibitors (used to treat breast cancer).
- 3. Osteogenesis imperfecta: Osteogenesis imperfecta is a rare form of osteoporosis that is present at birth. Osteogenesis imperfecta causes bones to break for no apparent reason.
- 4. Idiopathic juvenile osteoporosis: Idiopathic juvenile osteoporosis is rare. It occurs in children between the ages of 8 and 14 or during times of rapid growth. There is no known cause for this type of osteoporosis, in which there is too little bone formation or excessive bone loss.

Contents

- 1 Incidence and prevalence
 - ♦ 1.1 Incidence
 - 1.2 Prevalence
- 2 Product Information
 - ♦ 2.1 Like this report?
 - ◆ 2.2 Products in market
 - ♦ 2.3 Product pipeline
 - ♦ 2.4 Devices
 - 2.5 Pathways
- 3 Market Information
- 4 Clinical Trials
- 5 Intellectual Property
 - ♦ 5.1 Search strategy
 - ◆ 5.2 Top players and IPC classes
 - 5.3 Geographical Distribution and Treatment Approaches
 5.4 IP activity and Treatment Approaches
- 6 Conferences
- 7 Like this report?
- 8 Contact Dolcera

Incidence and prevalence



0.00

Incidence

- 1 in 3 women over 50 will suffer a fracture due to osteoporosis; this increases to 1 in 2 over 60.
- 1 in 5 men over 50 will suffer a fracture due to osteoporosis; this increases to 1 in 3 over 60.
- Approximately 1.6 million hip fractures occur each year worldwide, the incidence is set to increase to 6.3 million by 2050.
- The highest risk of hip fractures are seen in Norway, Sweden, Iceland, Denmark and the USA.
- Currently, there is an increasing incidence of hip fractures in the developed cities in Asia. 1 out of 4 hip fractures occur in Asia and Latin America. This number of hip fractures will increase to 1 in 2 by 2050.
- In the Middle East, the burden of osteoporosis in the general population is expected to increase and is becoming a heavy financial burden.7 • The annual incidence rate of osteoporotic fractures in women is greater than the combined incidence rates of heart attack, stroke and breast
- cancer. (International osteoporosis foundation)


Prevalence

- 28 million Americans (10 million with osteoporosis; 18 million with low bone mass); eight million American women and 2 million men (NWHIC)(approx 1 in 9 or 10.29% or 28 million people in USA).
- Total prevalence rate of osteoporosis in the middle- aged and elderly in China was 16. 1% in 2002. The prevalence rate among males was 11. 5% and among females was 19.9%.
- Prevalence increase to 2.2 million in 2006 and 3 million in 2021 in Australia.

• The prevalence of Khon Kaen (Thai rural area) women has osteporosis in femoral neck and lumbar spine is 19.3% and 24.7% respectively. (International osteoporosis foundation)

S.NO	Country/Region	Extrapolated Prevalence
1	USA	10 million cases (80% cases are women and 20% cases are men)
2	Australia	2.2 million
3	Middle east	18,603,593
4	Africa	47,233,590
5	Asia	359,862,754
6	Europe	80,590,570

Product Information



Overall categorization of osteoporosis treatments Like this report?

This is only a sample report with brief analysis Dolcera can provide a comprehensive report customized to your needs

Buy the customized report from Dolcera								
Patent Analytics Services	Market Research Services	Purchase Patent Dashboard						
Patent Landscape Services	Dolcera Processes	Industry Focus						
Patent Search Services	Patent Alerting Services	Dolcera Tools						

Products in market

Generic	Brand	Current Status	Туре	Company								
Antiresorptives	ntiresorptives											
	Bisphosphonates											
Alendronate	FOSAMAX®	Approved by US	Postmenopausal	Merck								
Risedronate	Actonel®	Approved by US/ES	Postmenopausal	Sanofi-Aventis/Procter & Gamble								
Ibandronate	Boniva?	Approved by US	Postmenopausal	Roche								
Etidronate	Didronel	Off Label		Proctor And Gamble								
Zoledronic Acid	Aclasta	Approved	Postmenopausal	Novartis								

		Selective Estrogen R	eceptor Modulators				
Raloxifene	Evista®	Approved by US		Osteoporosis	<u>Eli lilly</u>		
		Hormone Replac	ement Therapy				
Conjugated estrogen	Premarin®	Approved by US		Postmenopausal	<u>Wyeth</u>		
Conjugated estrogen	Cenestin?	Approved by US		Postmenopausal	Duramed		
Esterified estrogens	Estratab®	Approved by US		Postmenopausal	<u>Solvay</u>		
Esterified estrogens	Menesta	Approved by US		Postmenopausal	Monard	<u>h</u>	
Estradiol Transdermal System	Menostar	Approved by US	Approved by US Postmenopausal				
Estradiol Transdermal System	Vivelle Dot	Approved by US		Postmenopausal	<u>Noven</u>		
Estradiol	Estrace®	Approved by US		Postmenopausal	Bristol-	<u>Myers Squibb</u>	
Estradiol	Gynodiol	Approved by US		Postmenopausal	Novava	<u>IX</u>	
Tibolone	Livifem			Postmenopausal			
		Calcit	onin				
Calcitonin Salmon Injection	Miacalcin®	Approved by US	Postmenopausal	<u>Novartis</u>			
Calcitonin Salmon Nasal Spray	Miacalcin®	Approved by US		Postmenopausal	Novartis		
Calcitonin Salmon Nasal Spray	Fortical®	Approved by US		Postmenopausal			
Bone Forming Dru	gs						
Teripratide	Forteo®	Approved by US		Osteoporosis	<u>Pfizer</u>		
Drugs with Comple	ex Mechanism	s of Action					
Strontium Ranelate	Protelos	Not approved in USA	Postmenopausal osteoporosis	Servier			
Vitamin D							
Calcium		FDA is considering amending rules so now claim that calcium and Vitamin D i supplements can prevent osteoprorosis sexes	nsidering amending rules so that companies can that calcium and Vitamin D in their food nts can prevent osteoprorosis in all ages and both		FDA		
Product pipeline							
		Product	Pipeline				
DRUG		COMPANY	DESCR	IPTION		STAGE	
RANKL Inhibitors							
Denosumab		Atlantos, Amgen	A monoclor	al antibody		3	
Bisphosphonates							
Minodronate (YM	529)	Astellas	Nitrogen containin	g bisphosphonate			
Calcium Antagonis	st						
423557		Glaxosmithkline				1	


423337	Glaxosmilinkiine		
423562	Glaxosmithkline		1
Calcilytics (751689)	NPS and Glaxosmithkline	Calcilytics antagonize calcium receptors on parathyroid glands resulting in a transient release of the body?s own stores of parathyroid hormone (PTH).	1

Parathyroid Hormone			
768974	Glaxosmithkline	Parathyroid Hormone Agonist	1
Preos (rDNA origin)	NPS	Recombinant Parathyroid Hormone	Registration Filed
PTH1-34	Nastech	Intranasal Parathyroid hormone	2
PTH1-34	Novartis, Emisphere	Oral Parathyroid hormone	1
PTH Analogs	<u>Unigene</u>		2
Cathepsin k Inhibitor		•	
Relacatib (SB-462795)	GlaxoSmithkline		1
AAE581	<u>Novartis</u>		
MK-0822	Canadian Institutes of Health Research, Merck		2
Selective Estrogen Recept	or Modulators		
Bazedoxifene	Wyeth, Ligand	A Third-Generation Selective Estrogen Receptor Modulator for Treatment of Postmenopausal Osteoporosis	
Lasofoxifene (Oporia)	Pfizer,Ligand	A Third-Generation Selective Estrogen Receptor Modulator for Treatment of Postmenopausal Osteoporosis	NDA
Arzoxifene	<u>Eli lilly</u>		
Taromifene (Fareston)	Orion		
Calcitonin			
	Nastech		NDA
Salmon calcitonin	<u>Unigene</u>	Nasal	3
Salmon calcitonin	<u>Unigene</u>	Oral	2
Salmon calcitonin (SMC 021)	Novartis, Emisphere, Nordic	Oral	3
Salmon calcitonin	Nobex (Biocon)	Oral	3
Vitamin D			
ED 71	Bone/ Chugai	Activted Vitamin D derivative	3
Doxercalciferol (Hectorol)	Bone Care Int.	Synthetic Vitamin D	
Nitrates: Research is going	g on to determine if nitrates can prev	vent osteoporosis in women.	
Isosorbide mononitrate	St. Michael?s Hospital, Toronto		3
Nitroglycerine	<u>Canadian Institutes of Health</u> <u>Research (CIHR)</u>		3
HCT 1026 (NO releasing Derivative of NSAIDs)	<u>NicOx SA</u>		2
Selective Androgen Recep	otor Modulator (SARM)		
LGD-2941	Ligand, TAP		3
LGD-3303	Ligand, TAP		3
Ostarine	<u>GTx</u>		2
Intermittent Versus Continuous Androgen Suppression	Ontario Cancer Research Network		
Mk 0733	Merck		1
TH0229	Theratechnologies		
c-8500	Merck		2
c-3578	Merck		2


apomorphine	Ilex Oncology		2
Genistein	Primus Pharmaceuticals. Inc.	isoflavones have been shown to interact with animal and human estrogen receptors, causing effects in the body similar to those caused by the hormone estrogen.	Available
Soy estrogens	(NIAMS)		3
Hesperidin	Nestle clinical nutrition		3
Davallia Divaricata	National Taiwan University Hospital		1
Atorvaststin	[1]		
Potassium citrate	<u>Weill Medical College of Cornell</u> <u>University</u>		4
Phosphorus	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)		3

Devices

Hip Protector Pathways	Hip pads with special underwear with pockets	Children?s Mercy Hospital Kansas City
	Hip pads with special underwear with pockets	Children?'s Mercy Hospital Kansas City



PRODUCT PATHWAY



PRODUCT PIPELINE Market Information

	Prescription Trends in USA											
Source: Arch Intern Med. 2004;164:1525-1530												
1988 1990 1992 1994 1996 1998 2000 2002 2003												
Patients (Millions)	NA	0.6	0.6	0.5	1.2	2	2.6	2.8	3.6			
			Drugs F	Prescribed %	•							
Bisphosphonates (total)	1	9	17	14	48	49	54	71	73			
Alendronate	0	0	0	0	45	47	48	53	51			
Risedronate	0	0	0	0	0	0	4	17	22			
Etidronate	1	9	17	14	3	1	1	0	0			
Calcium	39	33	33	43	31	26	29	26	24			
Calcitonins	5	9	10	13	13	16	15	7	5			
Estrogens	35	25	33	27	17	12	8	5	3			
SERMs	0	0	0	0	0	9	14	12	12			

Clinical Trials

Trial No.	Condition	Description	Intervention	Therapy	Route of admn	Sponsors & Collaborators	Phase	Date
1	Postmenopausal Osteoporosis	Investigate Patient Preference On Dosing In Ibandronate And Risedronate in korean women	Ibandronate	Drug	Oral	GlaxoSmithKline	Phase IV	May-07
2	Osteoporosis Osteopenia	Texture Analysis for Postmenopausal Osteoporosis	Alendronate	Drug	Oral	University of Chicago	-	Mar-07
3	Osteoporosis	A Phase II Study Evaluating	SB-751689	Drug	Oral	GlaxoSmithKline	Phase II	May-07

		SB-751689 in Post-Menopausal						
		Women With Osteoporosis.						
4	Osteoporosis	Fall prevention program	Procedure	-	-	Sint Maartenskliniek ZonMw: The Netherlands Organisation for Health Research and Development		Apr-07
5	Osteoporosis Osteopenia	High Dosage Vitamin D and Osteoporosis	Cholecalciferol	Drug	Oral	University Hospital of North Norway	Phase IV	Jun-07
6	Osteoporosis	Effect of PTH(1-84)or Strontium Ranelate on Bone Formation Measured by Bone Markers	Parathyronine hormone	Drug	Oral	Nycomed	Phase IV	May-07
7	Post-Menopausal Osteoporosis	A Study of Quarterly Intravenous Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis.	ibandronate [Bonviva/Boniva]	Drug	Intravenous	Hoffmann-La Roche	Phase IV	Jul-07
8	Osteoporosis	A Study for Patients With Osteoporosis	1.Salmon Calcitonin 2.Teriparatide	Drug	Nose/intravenous	Eli Lilly and Company	Phase III	Jun-07
9	Osteoporosis	Safety/Efficacy of Zoledronic Acid and Alendronate on Bone Metabolism in Post Menopausal Women With Osteoporosis	Zoledronic acid and alendronate	Drug	Oral	Novartis	Phase III	May-07
10	Osteoporosis	Efficacy in Reducing Fractures and Safety of Zoledronic Acid in Men With Osteoporosis	zoledronic acid	Drug	Intravenous	Novartis	Phase III	Feb-07
11	Osteoporosis	Davallia Divaricata BL: The Use of Traditional Chinese Native Medicine for Osteoporosis	Gu-Sui-Bu (Davallia Divaricata)	Drug		National Taiwan University Hospital	Phase I	Jan-07
12	Osteoporosis	Dose Ranging Study - Macroflux PTH in Postmenopausal Women With Osteoporosis	Macroflux PTH	Drug	Subcutaneuos	The Macroflux Corporation	Phase II	Jun-07
13	Osteoporosis	Fosamax for Childhood Cancer Survivors	Alendronate	Drug	Oral	Chinese University of Hong Kong	Phase III	Oct-06
14	Osteoporosis	This study is currently recruiting patients.	Parathyroid Hormone (PTH)	Drug	Subcutaneuos	Nycomed	-	Feb-07
15	Osteoporosis	This study is currently recruiting patients.	Alendronate with cholecalciferol and Os-Cal with extra D	Drug	Oral	National Institute on Aging (NIA),Glaxosmithkline	Phase III	May-07
16	Primary Osteoporosis	Phase II/III Clinical Study of R484iv (Ibandronic Acid) for Primary Osteoporosis	Ibandronic acid	Drug	Oral	Chugai Pharmaceutical	Phase III	Mar-07
17	Postmenopausal Osteoporosis, Back pain and	Effect of Teriparatide Compared to	Teriparatide and risedronate	Drug	Oral/Subcutaneuos	Eli Lilly and Company	Phase III	Jul-07


	Spinal Fracture	Risedronate on Back Pain in Women With a Spine Fracture Caused by Osteoporosis						
18	Osteoporosis	BONDIR Study: A Study of Intravenous Bonviva (Ibandronate) After Recent Vertebral Osteoporotic Fracture in Patients With Osteoporosis.	lbandronate [Bonviva/Boniva]	Drug	Intravenous	Hoffmann-La Roche	Phase III	Jul-07

Intellectual Property


Search strategy

- Database/Vendor: Micropat
 Search scope: US Granted US Applications EP-A EP-B WO JP (bibliographic data only) DE-C,B DE-A DE-T DE-U GB-A FR-A; Claims
 Years: Issue/Publication Date: >20051231
 Search String: ((Osteoporosis OR (bone Near3 regeneration)) AND (treatment))
 Hits: 1261/982 patents (with/with out family members)
 Date of search: 14th September 2007

Top players and IPC classes




Geographical Distribution and Treatment Approaches



IP activity and Treatment Approaches





Conferences

- International Conference on Osteoporosis and Bone Research to be held on Oct 15-18, 2008 in Beijing, China.
 2008 IOF World Congress on Osteoporosis to be held on December 2-7, 2008, Bangkok, Thailand
 2007 World Congress on Osteoarthritis, December 6-9, 2007, Marriott Harbor Beach Resort & Spa in fabulous Ft. Lauderdale, Florida
 American Society of Bone and Mineral Research Annual Meeting, September 12-16, 2008, Montreal, Canada

Like this report?

This is only a sample report with brief analysis Dolcera can provide a comprehensive report customized to your needs

Buy the customized report from Dolcera		
Patent Analytics Services	Market Research Services	Purchase Patent Dashboard
Patent Landscape Services	Dolcera Processes	Industry Focus
Patent Search Services	Patent Alerting Services	Dolcera Tools

Samir Raiyani Email: info@dolcera.com Phone: +1-650-269-7952